$ABTI
ALTEROLA BIOTECH INC. Stock $abti

$abti Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000166357723000336 Filed on July 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$590.0K	-$450.0K	$1.330M
YoY Change	208.05%	-113.42%	-67.08%
% of Gross Profit
Research & Development		$320.0K	$46.42K
YoY Change		-84.83%	-98.09%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$580.7K	$70.00K	$1.897M
YoY Change	176.51%	-97.85%	-70.68%
Operating Profit	-$580.7K		-$1.897M
YoY Change	176.51%		-70.69%
Interest Expense	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$138.2K	$0.00
YoY Change
Pretax Income	-$730.0K	-$70.00K	-$1.900M
YoY Change	247.62%	-97.85%	-70.63%
Income Tax	$0.00	-$50.00K	-$150.0K
% Of Pretax Income
Net Earnings	-$718.8K	-$20.00K	-$1.742M
YoY Change	242.3%	-99.39%	-73.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	807.0M shares	807.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.00K	$10.00K	$10.00K
YoY Change	-35.0%	-84.33%	-83.33%
Cash & Equivalents	$36.55K	$8.890K
Short-Term Investments
Other Short-Term Assets	$190.0K	$190.0K	$190.0K
YoY Change	331.52%	1431.02%	1800.0%
Inventory	$1.009K	$986.00	$0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$231.2K	$237.2K	$240.0K
YoY Change	93.71%	85.75%	84.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.46M	$12.14M	$12.14M
YoY Change	3.85%	1.16%	1.17%
TOTAL ASSETS
Total Short-Term Assets	$231.2K	$237.2K	$240.0K
Total Long-Term Assets	$12.46M	$12.14M	$12.14M
Total Assets	$12.69M	$12.38M	$12.38M
YoY Change	4.73%	2.05%	2.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$678.0K	$611.8K	$610.0K
YoY Change	18.84%	12.77%	12.96%
Accrued Expenses	$283.1K	$254.9K	$250.0K
YoY Change	-30.32%	-35.72%	-37.5%
Deferred Revenue
YoY Change
Short-Term Debt	$1.370M	$1.260M	$1.260M
YoY Change	1275.92%	667.26%	687.5%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.334M	$2.127M	$2.130M
YoY Change	116.84%	104.63%	77.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$150.0K	$150.0K
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$150.0K	$150.0K
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.334M	$2.127M	$2.130M
Total Long-Term Liabilities	$0.00	$150.0K	$150.0K
Total Liabilities	$2.334M	$2.281M	$2.280M
YoY Change	90.07%	89.85%	90.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.30M	-$9.576M
YoY Change	25.85%	20.15%
Common Stock	$807.0K	$807.0K
YoY Change	0.55%	0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.36M	$10.10M	$10.10M
YoY Change
Total Liabilities & Shareholders Equity	$12.69M	$12.38M	$12.38M
YoY Change	4.73%	2.05%	2.06%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$718.8K	-$20.00K	-$1.742M
YoY Change	242.3%	-99.39%	-73.07%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$75.47K	$150.0K	-$1.040M
YoY Change	-54.52%	-94.32%	-2699.48%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$160.0K	-$140.0K
YoY Change
Cash From Investing Activities	-$18.90K	-$160.0K	-$139.8K
YoY Change		-101.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$802.5K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$68.45K	120.0K	$1.212M
YoY Change	6122.64%	-100.82%	-12221.59%
NET CHANGE
Cash From Operating Activities	-$75.47K	150.0K	-$1.040M
Cash From Investing Activities	-$18.90K	-160.0K	-$139.8K
Cash From Financing Activities	$68.45K	120.0K	$1.212M
Net Change In Cash	-$25.92K	110.0K	$32.69K
YoY Change	1039.75%	1937.04%
FREE CASH FLOW
Cash From Operating Activities	-$75.47K	$150.0K	-$1.040M
Capital Expenditures	$20.00K
Free Cash Flow	-$95.47K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001442999
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q1	us-gaap	Funds Held Under Reinsurance Agreements Asset FundsHeldUnderReinsuranceAgreementsAsset		usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2022Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	237184	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	127961	usd
CY2023Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12139779	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest		usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-156091
CY2023	dei	Entity Registrant Name EntityRegistrantName	Alterola Biotech, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1317032
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	47 Hamilton Square
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Birkenhead Merseyside
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	CH415AR
CY2023	dei	City Area Code CityAreaCode	151
CY2023	dei	Local Phone Number LocalPhoneNumber	601 9477
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	10661171	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	807047948	shares
CY2023	dei	Auditor Name AuditorName	Gries & Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Denver, Colorado 80246
CY2023	dei	Auditor Firm AuditorFirmId	6778
CY2023Q1	us-gaap	Cash Cash	8890	usd
CY2022Q1	us-gaap	Cash Cash	63816	usd
CY2022Q1	us-gaap	Funds Held Under Reinsurance Agreements Asset FundsHeldUnderReinsuranceAgreementsAsset	12409	usd
CY2023Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	37953	usd
CY2022Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	50686	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	189355	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	986	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1050	usd
CY2023Q1	us-gaap	Assets Assets	12376963	usd
CY2022Q1	us-gaap	Assets Assets	12127961	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	611805	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	542510	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	254864	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	396486	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1260434	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	98470	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2127103	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1037465	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	154313	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	164220	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2281416	usd
CY2022Q1	us-gaap	Liabilities Liabilities	1201685	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	802633333	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	807048	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	802633	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18927919	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18079554	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9576247	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7970510	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-63173	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	14599	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10095547	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10926276	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12376963	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12127961	usd
CY2023	ABTI	Accounting And Audit Fees AccountingAndAuditFees	106893	usd
CY2022	ABTI	Accounting And Audit Fees AccountingAndAuditFees	133036	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	363944	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	2432210	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46422	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	341286	usd
CY2023	us-gaap	Legal Fees LegalFees	179940	usd
CY2022	us-gaap	Legal Fees LegalFees	38248	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	347362	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	82913	usd
CY2023	ABTI	Consulting Fees ConsultingFees	443073	usd
CY2022	ABTI	Consulting Fees ConsultingFees	3155593	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	140409	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	194693	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	68938	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	93206	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1896981	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6471134	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1896981	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6471134	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-154524	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1742457	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6471134	usd
CY2023	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2022	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2023	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	806332740	shares
CY2022	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	769967671	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	136	usd
CY2021Q1	ABTI	Related Party Interest Forgiven RelatedPartyInterestForgiven	1544	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-403743	usd
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14023	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-343033	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-759119	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28622	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	368657	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12000000	usd
CY2022	ABTI	Stock Issued During Period Value S1 Registration StockIssuedDuringPeriodValueS1Registration	2399250	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3360000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6471134	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10926276	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-77772	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	137001	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50.0000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	321000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	481500	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1742457	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10095547	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1742457	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6471134	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	802500	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5759250	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-189535	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	136721	usd
CY2023	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount	12409	usd
CY2022	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount	-12409	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1050	usd
CY2023	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	12733	usd
CY2022	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	-50686	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	12409	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	2500	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	69295	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	444131	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-141638	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	376242	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1039792	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	44344	usd
CY2023	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	-139799	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-139799	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50295	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	368657	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	-1164964	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	542545	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	164220	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1212159	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9669	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32689	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34675	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	-87615	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	28622	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63816	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	519	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8890	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63816	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zCFuMlYrNtke" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – NATURE OF BUSINESS</b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20100402__20100503__us-gaap--StatementEquityComponentsAxis__custom--IssuanceOneMember_pdd">55,000,000</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210129__us-gaap--StatementEquityComponentsAxis__custom--IssuanceTwoMember_pdd">600,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a May 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding December 31, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction is being accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were <span id="xdx_90A_eus-gaap--Liabilities_c20210528_pp0p0">$389,721</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a consequence the company is now developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoids, cannabinoid-like, and non-cannabinoid APIs and will seek European novel food approval of certain ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Liabilities Liabilities	389721	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zy1fgGKdgQ36" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	254864	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	396486	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7500000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	802633333	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	802633333	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Loans Held For Sale Term LoansHeldForSaleTerm	P90D
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	75000	usd
CY2022Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	2250000	shares
	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors	75000	usd
CY2023	ABTI	Shareholder Advances ShareholderAdvances	1260434	usd
CY2023Q1	us-gaap	Capital Capital	1890623	usd
	us-gaap	Profit Loss ProfitLoss	-9576247	usd

Files In Submission

Name	View Source	Status
0001663577-23-000336-index-headers.html	Edgar Link	pending
0001663577-23-000336-index.html	Edgar Link	pending
0001663577-23-000336.txt	Edgar Link	pending
0001663577-23-000336-xbrl.zip	Edgar Link	pending
abti-20230331.xsd	Edgar Link	pending
abti10k033123.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abti-20230331_def.xml	Edgar Link	unprocessable
abti-20230331_lab.xml	Edgar Link	unprocessable
abti-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abti10k033123_htm.xml	Edgar Link	completed
abti-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABTI
ALTEROLA BIOTECH INC. Stock $abti

2023 Q2 Form 10-K Financial Statement

#000166357723000336 Filed on July 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI ALTEROLA BIOTECH INC. Stock $abti

2023 Q2 Form 10-K Financial Statement

#000166357723000336 Filed on July 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI
ALTEROLA BIOTECH INC. Stock $abti